Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Andrew Hall M.Sc. | CEO & Director | 680.6k | -- | -- |
| Ms. Brittany Davison C.A., CPA | Chief Accounting Officer, Corporate Secretary & Director | 207.9k | -- | 1990 |
| Delphine Davan | Senior Director of Communications & Investor Relations | -- | -- | -- |
| Mr. Stephan Fiset M.B.A., M.Sc. | Vice President of Clinical Research | -- | -- | -- |
IMV Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 63
Description
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX, an immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
July 10, 2023 at 12:00 AM UTC
25-NSE: Notification filed by national security exchange to report the removal from listing and registration of matured